Skip to main content
Clinical Trials/JPRN-UMIN000040586
JPRN-UMIN000040586
Completed
未知

Prospective observational study investigating the impact of treatment sequence using regorafenib and FTD/TPI for metastatic colorectal cancer on overall survival - OSERO study

Kyushu Study group of Clinical Cancer0 sites501 target enrollmentJuly 1, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
colorectal cancer
Sponsor
Kyushu Study group of Clinical Cancer
Enrollment
501
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2020
End Date
June 30, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kyushu Study group of Clinical Cancer

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Prior treatment with regorafenib or FTD/TPI 2\)Patients with active multiple cancers 3\)Patients who have symptomatic brain metastases. 4\)Patients with diabetes mellitus, hyper tension, angina unstable, or symptomatic congestive heart failure (NYHA III/IV) that cannot be controlled adequately with medication. 5\)Patients whom a lead investigator or primary physician deems are not appropriate for this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials